Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat
Catherine J Leader, Darren J Kelly, Ivan A Sammut, Gerard T Wilkins, Robert J Walker
Physiological Reports | WILEY | Published : 2020
Hypertension plays an important role in the development and progression of chronic kidney disease. Studies to date, with mineralocorticoid receptor antagonists (MRA), have demonstrated varying degrees of results in modifying the development of renal fibrosis. This study aimed to investigate whether treatment with a MRA commenced following the establishment of hypertension, a situation more accurately representing the clinical setting, modified the progression of renal fibrosis. Using male Cyp1a1Ren2 rats (n = 28), hypertension was established by addition of 0.167% indole-3-carbinol (w/w) to the rat chow, for 2 weeks prior to treatment. Rats were then divided into normotensive, hypertensive (..View full abstract
The funding was provided by the Department of Medicine (University of Otago, New Zealand), a Laurenson Award from the Otago Medical Research Foundation (Dunedin, New Zealand), the Healthcare Otago Charitable Trust (Dunedin, New Zealand), Lotteries Health New Zealand, and the Maurice and Phyllis Paykel Trust (New Zealand).